Perforin is a pore-forming, immune protein that functions to deliver an apoptotic cocktail of proteins into a target pathogen. Recent studies of the bacterial cholesterol-dependent cytolysins (CDCs) have provided a model for perforin's pore-forming mechanism. Both perforin and CDC family members share a conserved β-sheet flanked by two clusters of α-helices. Within the CDCs, these helices refold into two transmembrane β-hairpins, TMH1 and TMH2. Based upon structural conservation and electron microscopy imaging, the analogous helices within perforin are predicted to also be membrane inserting; however, these regions are approximately twice the length of the CDC TMHs. To test the membrane-insertion potential of one of these regions, chimeras were created using a well-characterized CDC, perfringolysin-O (PFO), as the backbone of these constructs. PFO's TMH2 region was replaced with perforin's corresponding helical region. Although hemolytic activity was observed, the chimera was poorly soluble. A second chimera contained the same region truncated to match the length of the PFO TMH2 region. The truncated chimera demonstrated improved solubility, significant hemolytic activity and the ability to form pores characteristic of those created by PFO. These results provide the first evidence that perforin's helices function as TMHs and more importantly narrows the residues responsible for membrane insertion.
Introduction
Natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) function in innate and adaptive immunity to recognize and kill infected and/or abnormal cells. Once NK cells or CTLs associate with a target cell, they release a deadly mixture of proteins, including perforin, granzymes (serine proteases) and granulysin (an antibacterial toxin), into the immunological synapse. Subsequently, perforin binds to the membrane of the target cell and forms a pore facilitating the entry of the granzymes and granulysin, which ultimately induce cell death (Voskoboinik et al., 2015) .
Human perforin is a Ca 2+ -dependent (Voskoboinik et al., 2005) , pore-forming protein that is a member of the membrane-attack complex (MAC)/perforin (MACPF) family of proteins. Members of this family were originally named due to sequence similarity between the terminal components of complement (MAC) and perforin; however, several hundred MACPF proteins have now been identified based upon a signature MACPF motif (Rosado et al., 2008) . The crystal structures of several eukaryotic MACPF proteins (complement components C6 (Aleshin et al., 2012b) , C5b6 (Aleshin et al., 2012a) , C8α (Hadders et al., 2007) , C8 (Lovelace et al., 2011) and perforin (Law et al., 2010) ) have been determined and show structural homology to the bacterial family of pore-forming toxins known as cholesterol-dependent cytolysins (CDCs). The common central feature of the MACPF/CDC superfamily is a twisted, antiparallel β-sheet flanked by two α-helical bundles (Law et al., 2010; Dunstone and Tweten, 2012) . Most of our understanding of the pore-forming mechanism of MACPF proteins has been modeled after the well-characterized CDCs.
CDCs are virulence factors secreted from gram-positive and gram-negative bacteria (Reboul et al., 2014) . The CDC poreforming mechanism was initially elucidated through work with perfringolysin-O (PFO) from Clostridium perfringens (Rossjohn et al., 1997) . Initially, a PFO monomer binds to cholesterol through an undecapeptide located in the C-terminal, Ig-like domain (Dowd and Tweten, 2012) . Recruitment of 30-50 additional monomers forms a homo-oligomeric pre-pore complex that is stabilized through intermolecular interactions between the core β-sheets of adjacent PFO monomers (Shatursky et al., 1999; Ramachandran et al., 2004) . The two α-helical bundles that flank this β-sheet refold into extended transmembrane β-hairpins, termed TMH1 and TMH2, forming a β-barrel pore (Shepard et al., 1998; Shatursky et al., 1999; Hotze et al., 2002) .
Analyses of the structural homology between perforin and CDC family members predict that the helical bundles within perforin (termed CH for clusters of helices (Law et al., 2010) ) are most likely to refold into β-hairpins, similar to the TMHs in the CDCs, ultimately resulting in the formation of a β-barrel pore. However, details of this assumption have yet to be supported experimentally. In this study, we used PFO as a scaffold to determine whether the CH regions of perforin (PRF), specifically CH2, could functionally substitute for the analogous TMH2 domain in PFO. PFO/PRF chimeras were created by replacing the known, membrane-inserting TMH2 region of PFO (Shatursky et al., 1999) with the putative, membraneinserting CH2 region of perforin (Baran et al., 2009; Law et al., 2010) . Substitution of the entire perforin CH2 region resulted in a poorly expressed, hemolytically active chimera. Truncation of the CH2 region (to match the size of the TMH2 domain) resulted in a chimera with enhanced expression, greater solubility and increased hemolytic activity. Homo-oligomeric complexes of the chimera were SDS-resistant and formed pore-like structures in the presence of membranes. Both are well-documented features of PFO complexes. In addition to forming homo-oligomeric complexes, the truncated chimera formed functionally active mixed oligomeric complexes with PFO. Collectively, these results provide the first experimental evidence that the CH2 region of perforin functions in membrane insertion during pore formation.
Materials and methods

PFO and chimera construct design
The pRT20 plasmid encoding perfringolysin-O C459A was a generous gift from Dr Rodney K. Tweten, University of Oklahoma. This construct encodes a variant of PFO (referred to as PFO in this manuscript) that contains an additional 36 N-terminal residues (MGGSHHHHHHGMASMTGGQQMGRDLYDDDDKDRWGS), including a 6× His tag, and a nucleotide substitution that changes the sequence encoding Residue 459 from a Cys to an Ala (Shepard et al., 1998) . This substitution prevents oligomerization during overexpression but does not impact the overall function of the protein. Two chimeras were designed by replacing the nucleotides encoding the TMH2 domain of PFO in this construct with nucleotides encoding the CH2 domain of perforin, while all other residues within PFO were conserved. Specifically, the chimeras PFO/ PRF 220-278 and PFO/PRF 232-263 contain the sequences for the mature Residues 220-278 and 232-263, respectively, from the CH2 region of perforin in place of the DNA encoding the PFO TMH2 domain (mature Residues 256-287). Additionally, the PFO/PRF 220-278 chimera was designed to eliminate a free thiol (C221A), while the nucleotides encoding Cys 236 and Cys 258 were retained as they form a disulfide in the murine perforin crystal structure (Law et al., 2010) . The chimeric genes were codon optimized for bacterial expression, synthesized and subcloned into the NdeI and XhoI sites of the pET17b vector by GENEWIZ, Inc. (South Plainfield, NJ).
Protein expression and purification
All plasmids were transformed into BL21 Escherichia coli cells (New England Biolabs, Ipswich, MA) and transformants were grown in LB medium supplemented with 50 μg/ml carbenicillin (EMD Millipore, Billerica, MA). PFO was expressed and purified as previously described (Weiland et al., 2014) . Overnight cultures of chimeric transformants were used to inoculate 500 ml of LBcarbenicillin medium and cultures were grown at 37°C with shaking until an OD 600 = 0. Lysates were rocked for 30 min and cell debris was pelleted by centrifugation at 10 000×g for 20 min. His-tagged proteins were purified from the IPTG-induced cultures using Ni-NTA Superflow columns (GE Healthcare Life Sciences, Piscataway, NJ) connected to an AKTA Purifier FPLC (GE Healthcare). The supernatants were loaded onto the column and washed with at least three column volumes of buffer composed of 50 mM Tris, 300 mM NaCl and 20 mM imidazole, pH 8.0. Proteins were eluted using a gradient of 0-100% limit buffer (50 mM Tris, 300 mM NaCl, and 500 mM imidazole, pH 8.0) over 1 h, at a flow rate of 0.5 ml/min. Fractions were collected and those containing protein peaks were pooled, dialyzed against 50 mM sodium phosphate, 150 mM NaCl, pH 7.5, and stored at −70°C in 10% final glycerol.
Western blotting and quantitative analysis
Western blots were used to detect the His-tagged proteins (the His tag was left intact for all experiments) and to estimate the concentration of column-purified chimeric proteins. Samples were mixed with 6× SDS-loading buffer (no reducing agents or boiling), and loaded onto a 10% SDS-PAGE gel containing 1% 2,2,2-trichloroethanol (TCE). After separation, proteins were visualized by activating TCE at 300 nm for 5 min (Ness et al., 2015) and recorded using a ChemiDoc MP imager (Bio-Rad, Hercules, CA). If the end result was a western blot, the TCE was not activated since this process inhibits detection of the His tag (data not shown). For western blotting, the proteins in the gel were transferred onto NitroBind nitrocellulose (0.22 μm; GE Healthcare) using a trans-blot SD semi-dry transfer cell (Bio-Rad) at 10 V for 30 min. The membrane was blocked overnight in 10% non-fat dry milk in TBS-T (20 mM Tris, 150 mM NaCl, and 0.05% Tween 20, pH 7.4) with rocking at 4°C. The membrane was incubated with 0.5 μg/ml THE TM anti-His monoclonal antibody [HRP] (GenScript, Piscataway, NJ) in blocking buffer for 1 h while rocking. The membrane was washed with TBS-T and visualized using Pierce's TM ECL western blotting substrate (Fisher Scientific). The concentrations of PFO and PFO/PRF 232-263 preparations were determined using a quantitative western blot approach and by measuring their absorbance at λ 280 with a theoretical extinction coefficient. Both techniques yielded similar concentrations; therefore, with the poorly expressing PFO/PRF 220-278 chimera, the concentration was determined by comparing the band density on a western blot to known amounts of a PFO control on the same blot and using the ChemiDoc MP Image Lab TM software (Bio-Rad) to quantitate the sample (data not shown).
Hemolytic assays
Hemolytic assays were performed following a modified published procedure (Tweten, 1988) . Rabbit erythrocytes (Colorado Serum Company, Denver, CO) were washed and resuspended to 1.0 × 10 8 cell/ml in the assay buffer (50 mM sodium phosphate, 150 mM NaCl and 0.1 mg/ml BSA, pH 7.5). Reactions were performed by mixing 140 μl of the assay buffer, 35 μl of erythrocytes and 50 μL of the protein of interest in an individual well within a 96-well plate. The reactions were incubated at 37°C for 35 min with mixing by vortex every 7 min. Following the incubation, unlysed cells were pelleted by centrifugation at 2000×g for 10 min and the supernatants were transferred to a new well. Hemolysis was measured at λ 405 . Combination hemolytic assays were performed by mixing 50 μl of sublytic dilutions of the PFO/PRF 232-263 chimera with 50 μl of PFO 0 (0.1 pg/μl) for 20 min at 23°C. Mixtures were then added to 125 μl of 2.8 × 10 7 cell/ml, incubated at 37°C for 35 min, after which hemolysis was measured.
Preparation of rabbit ghost membranes
Rabbit erythrocytes were washed with 20 mM sodium phosphate and 135 mM NaCl, pH 7.4 and centrifuged at 4000×g to pellet the cells. The cells were lysed by incubating with 20 mM sodium phosphate, pH 7.4 for 20 min with rocking. Lysates were centrifuged at 17 000×g to pellet the membranes and the supernatants were removed. Membranes were resuspended and washed three more times in the lysis buffer. After the final wash, the membranes were resuspended in 20 mM sodium phosphate, 135 mM NaCl, pH 7.4 and stored on ice until ready to use.
SDS-agarose gel electrophoresis and immunoblot analyses
Denaturing agarose gel electrophoresis (AGE) was performed according to the previously published procedure (Shepard et al., 2000) . Proteins were transferred to nitrocellulose overnight via wet transfer at 15 V in 25 mM Tris, 192 mM glycine and 3.5 mM SDS.
The membrane was blocked in 10% non-fat dry milk in TBS for 1 h at room temperature, washed three times with TBS and incubated with 0.5 μg/ml THE TM anti-His monoclonal antibody [HRP] for 1 h at room temperature. The membrane was washed two times with TBS, once with TBS-T, visualized with the ECL reagent and documented using the imaging system.
Electron microscopy
Ghost membranes were incubated with 600 nM PFO or chimeric protein at 37°C for 45 min. Samples were stored on ice and shipped to the Electron Microscopy Center at the University of South Carolina. Upon arrival, specimens were vortexed at a moderate speed prior to placing 5-10 μl onto a piece of parafilm in a petri dish. A carbon formvar-coated 300 mesh copper grid was floated on the drop with the coated side in contact with the specimen. The petri dish was covered and allowed to stand for 3 min. The grid was gently removed and the sample droplet was dried by carefully touching the edge of the grid with a clean piece of filter paper. The grid was stained with 3% aqueous uranyl acetate (UA) solution for 3 min by floating it on a droplet of UA in a covered petri dish. The grid was gently removed and dried with filter paper as described above. Once the grid was completely dry, images were obtained with a Hitachi H8000 TEM running at 150 kV.
Results
PFO/PRF chimeras exhibit hemolytic activity
The crystal structures of PFO and murine perforin show that both proteins share a similar core structure comprising a four-stranded, antiparallel β-sheet flanked by α-helices (Fig. 1A) . The TMH1 and TMH2 α-helices of PFO are known to refold into membraneinserting β-hairpins during pore formation (Shepard et al., 1998; Shatursky et al., 1999) . Structural homology strongly suggests that the perforin CH1 and CH2 regions behave similarly but direct evidence to support this assumption is lacking. Since the murine protein is the only perforin protein that has been crystallized, the murine sequence (GenBank Accession# AAA39910) was aligned with human perforin (GenBank Accession# AAA60065) in order to identify the corresponding CH2 region of the human protein (Fig. 1B) .
To determine whether human perforin CH2 could functionally substitute for the TMH2 region of PFO, a construct was created which contained the entire PFO sequence with the exception of the region coding for the TMH2 domain (purple; Fig. 1C) , which was replaced with the entire CH2 coding region of human perforin (blue and red; Fig. 1C ). Expression and purification resulted in very low amounts of soluble PFO/PRF 220-278 protein (~50 µg/l). While an over-expressed band could not be visualized by SDS-PAGE (data not shown), western blot analyses revealed a specific band for the chimera with a higher molecular weight than PFO ( Fig. 2A, Lanes 2  and 3) . The difference in mobility reflects the larger size of perforin's CH2 region (59 aa), which is nearly twice the size of the PFO TMH2 domain (32 aa). Several attempts were made to optimize protein expression by varying expression temperatures, concentrations for IPTG induction, shaking speeds and bacterial cell lines, but these efforts only resulted in increased inclusion body formation. Attempts to refold this construct through dilution and on-column approaches were also unsuccessful. The larger CH2 region of perforin most likely disrupts the proper folding of PFO resulting in insoluble products.
Although the PFO/PRF 220-278 protein was poorly soluble, very small amounts of protein are required to test hemolytic activity. An average of 50 pg PFO induced 50% lysis when purified protein was mixed with rabbit erythrocytes (Fig. 2C, filled circles) . Both fresh and frozen samples demonstrated similar levels of activity (data not shown). Additionally, no differences were observed when hemolytic assays were performed under reducing or non-reducing conditions (data not shown). PFO/PRF 220-278 retained~7% of PFO's hemolytic activity (Fig. 2C, filled triangles) ; however, further characterization was hindered by its insolubility.
Given that the α-helices of PFO TMH2 refold into a membrane inserting, amphipathic β-hairpin, we returned to the human perforin CH2 sequence to search for an alternating hydrophobic/hydrophilic segment that could interact with the lipid membrane and interior of the pore while also having a hydrophilic break to serve as a turn for the β-hairpin. These characteristics were identified and are indicated in Fig. 1B and Supplementary Fig. S1 . The 32-amino acid sequence indicated by the red bar (Residues 232-263) encompasses both of these features within the human perforin CH2 domain and is the exact same length as the TMH2 region of PFO. Therefore, a second chimera was designed by replacing the PFO TMH2 segment with the truncated perforin CH2 region to create the PFO/PRF 232-263 construct (Fig. 1C) . Consequently, the chimera was tested to determine whether this change improved protein expression, protein folding and overall activity.
Expression levels of PFO/PRF 232-263 were significantly better (0.5 mg/L) than the PFO/PRF 220-278 construct. After Ni-NTA purification, pooled protein fractions containing the PFO/PRF 232-263 chimera yielded a fairly pure protein with a mobility equal to that of PFO ( Fig. 2A and B) . PFO/PRF 232-263 also demonstrated significantly greater hemolytic activity (Fig. 2C , filled squares) compared with PFO/PRF 220-278, although it was still only 15% the activity of PFO. The reduced activity may be due to differences in Fig. 1 Comparison and alignment of PFO TMH2 and perforin CH2 regions. (A) Shown are the structures of PFO (PDB code: 1PFO) and murine PRF (PDB code: 3NSJ). PFO and PRF share a common fold that includes a bent, four-stranded, antiparallel β-sheet (orange) flanked by two α-helical bundles (TMH and CH, respectively). The TMH2 region (purple) in PFO and the analogous, putative membrane-inserting domain in perforin (CH2, red and blue) are indicated. (B) A sequence alignment of the murine and human CH2 regions is shown. The alternating hydrophobic (highlighted in yellow) and hydrophilic residues in these sequences are indicative of an amphipathic β-hairpin. The underlined residues most likely comprise a turn region. PFO TMH2 was not part of the alignment but is shown for comparison. (C) Two PFO chimeras were created by replacing the TMH2 domain of PFO (purple) with perforin CH2 Residues 220-278 (blue and red) or 232-263 (red) to generate PFO/PRF 220-278 and PFO/PRF 232-263, respectively. *PFO TMH2 in part C is numbered using the mature residues, whereas PFO TMH2 in part B corresponds to crystal structure of PFO which includes the signal peptide.
the efficiency of interactions between monomers of PFO/PRF 232-263 compared to PFO.
Sublytic concentrations of PFO enhance lytic activity of a PFO/PRF chimera PFO chimeras containing the TMH2 regions of complement proteins (C8α and C9) were previously shown to possess a similar level of hemolytic activity (10-15% of PFO), (Weiland et al., 2014) as demonstrated by PFO/PRF 232-263. The activities of these chimeras were enhanced by the addition of sublytic concentrations of PFO indicating that the chimeras interact with PFO to form active, hetero-oligomeric complexes similar to homo-oligomeric PFO complexes. In order to determine whether PFO can similarly enhance the hemolytic activity of the PFO/PRF 232-263 chimera, sublytic amounts of PFO were mixed with PFO/PRF 232-263 and a combination hemolytic assay was performed. No lysis was detected after erythrocytes were treated with 5 pg PFO; therefore, this amount was selected for the sublytic PFO treatment (PFO 0 ). As expected, when PFO was combined with PFO 0 , a typical hemolytic curve was observed (Fig. 3, filled circles) . Under normal conditions, PFO/PRF 232-263 does not initiate lysis until >50 pg is mixed with the rabbit erythrocytes (Fig. 2C) . No lysis was detected in this assay when up to 50 pg of PFO/PRF 232-263 was tested (filled squares). However, when PFO 0 was mixed with sublytic amounts of PFO/ PRF 232-263, hemolysis was detected up to~25% where it leveled out with increasing amounts of sublytic concentrations of chimera (open circles).
The PFO/PRF chimera forms SDS-resistant complexes PFO is unique in that it forms SDS-resistant oligomeric complexes in the presence of cholesterol-rich membranes (Shepard et al., 1998) . Since the complexes are resistant to SDS treatment, they can be separated using SDS-AGE, and His-tagged oligomers can be detected by western blotting with anti-His tag antibodies (Fig. 4, Lane 4) . To test the ability of the truncated CH2 from perforin to substitute for PFO's TMH2 region, PFO/PRF 232-263 was tested for oligomerization in the presence of membranes. When either PFO or PFO/PRF 232-263 was incubated with membranes, most of the monomeric protein was incorporated into a broad, high-molecular weight smear (Fig. 4 , Lanes 4 and 5). These smears correspond to the formation of oligomeric complexes of varying size. Both PFO and PFO/PRF 232-263 appeared to form complexes equally well, but only in the presence of membranes (Fig. 4, Lanes 1 and 2) . No complexes were observed in the absence of PFO or the chimera (Fig. 4, Lane 3) .
The PFO/PRF chimera forms pores similar to PFO PFO has been clearly shown to participate in pore-forming activities; therefore, it is most likely that the SDS-resistant oligomeric complexes observed in the oligomerization assay were monomers aggregating on the membranes during the pore formation process. Electron microscopy was used to visually confirm that the PFO complexes were actively forming pores on the rabbit erythrocyte membranes (Fig. 5A) . The hemolytically active PFO/PRF 232-263 chimera formed pore-like structures similar to PFO (Fig. 5B ). Both proteins produced circular, pore-like structures with diameters of~40 Å.
Discussion
Perforin and the bacterial CDCs share functional similarities in that both are well known for their pore-forming activities in immune defense and bacterial virulence, respectively. Structural homology suggests that perforin mediates pore formation in a manner similar to the CDCs. One significant difference is that the CDCs undergo a major conformational change during the pre-pore to pore conversion, which involves a vertical collapse to facilitate membrane entry by the TMH regions (Dunstone and Tweten, 2012) . For perforin, the CH regions are twice the length of the CDC TMHs (Law et al., 2010) . Therefore, upon membrane binding, the CHs are expected to unravel and insert during pore formation without significantly altering the overall height of the complex. Results from electron microscopy support this model, but the residues involved with membrane insertion have not been elucidated experimentally (Reboul et al., 2015) . This study used a chimeric approach to evaluate perforin's CH2 region as a putative membrane-inserting domain. This region is of particular interest because the analogous regions of other MACPF/ CDC family members have been shown to be important for controlling pore formation in addition to acting as a site of complement regulation by the MAC inhibitor CD59 (Lockert et al., 1995; Schuerch et al., 2005; Huang et al., 2006; Hadders et al., 2012) . Our initial approach was to substitute the entire CH2 region of perforin in place of PFO's TMH2 region . Although the CH2 is approximately twice the size of the PFO TMH2 domain, this method has been successfully used to evaluate similarly sized regions of the complement components C8α and C9 (Weiland et al., 2014) . The PFO/PRF 220-278 chimera retained hemolytic activity, but was poorly soluble, complicating further characterization. This construct was re-designed to truncate the CH2 region to match the exact residue length of PFO's TMH2 region. The truncation was centered on the region of CH2 most likely to form an amphipathic β-hairpin. Shatursky et al. previously showed that the TMH2 region of PFO is responsible for membrane insertion by individually mutating PFO Residues 288-311 to Cys and subsequently labeling with a sulfhydryl-specific NBD dye that fluoresces in the presence of a hydrophobic environment. Their results support the formation of an amphipathic β-hairpin through the detection of fluorescence at alternating residues. Alignment of the PRF CH2 232-263 region with PFO TMH2 shows the Cterminal region of the PFO CH2 232-263 has hydrophobic residues that directly align with the identified PFO TMH2 membraneassociating residues and the putative turn region is composed of polar residues as seen with the PFO TMH2 sequence; however, the N-terminal region of alternating hydrophobic residues is displaced by one position with respect to the identified PFO TMH2 membrane-associating residues, Supplementary Fig. S1 .
The truncated PFO/PRF 232-263 construct demonstrated marked improvements in hemolytic activity in comparison to PFO/ PRF 220-278. The activity for the chimera was not expected to be equivalent to PFO's level of hemolysis activity since pore formation is dependent not only on the TMH2 region but also on native intermolecular interactions with the TMH1 region. Although the PFO/ PRF 232-263 region encompasses the same number of residues as the PFO TMH2, the one residue displacement of the PRF CH2 hydrophobic residues with the known membrane-inserting residues of PFO TMH2, on the N-terminal side of the PFO CH2 substitution, likely does not properly align with PFO TMH1 during prepore formation which contributes to decreased hemolytic activity, Supplementary Fig. S1 . While perforin's truncated CH2 region can substitute in part for TMH2, it does not mediate the same interactions with TMH1. We are currently exploring the possibility that hemolytic activity could be further enhanced, possibly even to PFO levels, by performing a second substitution between perforin's CH1 and PFO's TMH1 regions within the PFO/PRF 232-263 construct. This substitution would permit more natural interactions between perforin's CH1 and CH2 regions within the PFO framework.
EM images were collected to verify that the hemolytic activity of PFO/PRF 232-263 was the result of pore formation. Comparisons between PFO and chimeric pores showed both proteins form numerous pore-like structures of similar diameter. The pore size is in agreement with previously published results for PFO (Hotze et al., 2001; Dang et al., 2005) . Additionally, these pores are SDS resistant, a feature previously documented for PFO pores. PFO Y181A , a mutant trapped in the pre-pore conformation, is incapable of forming SDS-resistant complexes, suggesting that SDSresistance is only conferred when both TMHs insert and the final pore state has been achieved (Hotze et al., 2002) . The TMHs participate in cooperative folding and assembly; therefore, neither can enter the membrane without the other (Lukoyanova et al., 2015) making insertion of the pre-pore complex an 'all or none process'. The SDS-resistant complexes formed by PFO/PRF 232-263 provide further evidence that the chimera forms a mature pore-like PFO. In a similar chimeric study, the TMH2 regions from complement proteins (C8α and C9), while able to functionally substitute for the TMH2 region of PFO, were unable to form SDS-resistant complexes (Weiland et al., 2014) without the presence of wild-type PFO. Additionally, sublytic amounts of PFO (PFO 0 ) enhanced the hemolytic activity of PFO/PRF 232-263. As the amounts of chimera were increased relative to PFO 0 , the hemolytic activity leveled off due to saturation with sublytic concentrations of the chimera. This suggests that at low molar excesses, the perforin CH2 substitution is capable of interacting with PFO's TMH1 to form a pore and the PFO/PRF 232-263 chimera functions as a suitable replacement for PFO.
Although the perforin CHs have been predicted, based upon structural conservation and modeling by electron microscopy, to refold and participate in membrane insertion, our results provide the first experimental evidence to support their role in membrane insertion, pore formation and hemolysis. Importantly, the perforin CH2 region is a suitable replacement for the PFO TMH2 domain. Our data suggest that the key membrane-inserting domain can be narrowed to a 32-amino acid segment (Residues 232-263) within the 59 amino acid CH2 region of perforin. These data are in agreement with previous predictions (Baran et al., 2009) . Finally, the use of this chimeric system may allow for the identification of key membrane-inserting residues within perforin CH1 or other putative TMH regions within other CDC/MACPF family members.
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